339 related articles for article (PubMed ID: 15075511)
1. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine.
Macías J; Castellano V; Merchante N; Palacios RB; Mira JA; Sáez C; García-García JA; Lozano F; Gómez-Mateos JM; Pineda JA
AIDS; 2004 Mar; 18(5):767-74. PubMed ID: 15075511
[TBL] [Abstract][Full Text] [Related]
2. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.
Macías J; Mira JA; López-Cortés LF; Santos I; Girón-González JA; González-Serrano M; Merino D; Hernández-Quero J; Rivero A; Merchante N; Trastoy M; Carrillo-Gómez R; Arizcorreta-Yarza A; Gómez-Mateos J; Pineda JA
Antivir Ther; 2006; 11(7):839-46. PubMed ID: 17302246
[TBL] [Abstract][Full Text] [Related]
3. Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy.
Fuster D; Planas R; Muga R; Ballesteros AL; Santos J; Tor J; Sirera G; Guardiola H; Salas A; Cabré E; Ojanguren I; Barluenga E; Rey-Joly C; Clotet B; Tural C
AIDS Res Hum Retroviruses; 2004 Dec; 20(12):1293-7. PubMed ID: 15650421
[TBL] [Abstract][Full Text] [Related]
4. Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection.
Berenguer J; Bellón JM; Miralles P; Alvarez E; Castillo I; Cosín J; López JC; Sánchez Conde M; Padilla B; Resino S
Clin Infect Dis; 2008 Jan; 46(1):137-43. PubMed ID: 18171229
[TBL] [Abstract][Full Text] [Related]
5. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
[TBL] [Abstract][Full Text] [Related]
6. Highly active antiretroviral therapy-related hepatotoxicity in human immunodeficiency virus and hepatitis C virus co-infected patients with advanced liver fibrosis in Taiwan.
Chou CC; Tsai HC; Wu KS; Sy CL; Chen JK; Chen YS; Lee SS
J Microbiol Immunol Infect; 2016 Aug; 49(4):546-53. PubMed ID: 25440980
[TBL] [Abstract][Full Text] [Related]
7. Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon.
Mbougua JB; Laurent C; Kouanfack C; Bourgeois A; Ciaffi L; Calmy A; Gwet H; Koulla-Shiro S; Ducos J; Mpoudi-Ngolé E; Molinari N; Delaporte E
BMC Public Health; 2010 Mar; 10():105. PubMed ID: 20193053
[TBL] [Abstract][Full Text] [Related]
8. Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.
Guaraldi G; Zona S; Orlando G; Carli F; Stentarelli C; Luzi K; Garlassi E; Menozzi M; Bagni P; Adorni F
Clin Drug Investig; 2011 Nov; 31(11):759-67. PubMed ID: 21919542
[TBL] [Abstract][Full Text] [Related]
9. Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.
Torti C; Costarelli S; De Silvestri A; Quiros-Roldan E; Lapadula G; Cologni G; Paraninfo G; Castelnuovo F; Puoti M; Carosi G;
Drug Saf; 2007; 30(12):1161-9. PubMed ID: 18035868
[TBL] [Abstract][Full Text] [Related]
10. Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy.
Pineda JA; Macías J
J Antimicrob Chemother; 2005 Apr; 55(4):417-9. PubMed ID: 15731202
[TBL] [Abstract][Full Text] [Related]
11. Levels of serum markers of liver inflammation and fibrosis in patients with chronic hepatitis C virus infection according to HIV status and antiretroviral use.
Connoy A; Turner J; Núñez M
AIDS Res Hum Retroviruses; 2011 Jul; 27(7):719-25. PubMed ID: 21128862
[TBL] [Abstract][Full Text] [Related]
12. HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension.
Reiberger T; Ferlitsch A; Sieghart W; Kreil A; Breitenecker F; Rieger A; Schmied B; Gangl A; Peck-Radosavljevic M
J Viral Hepat; 2010 Jun; 17(6):400-9. PubMed ID: 19780945
[TBL] [Abstract][Full Text] [Related]
13. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus.
Martinez-Sierra C; Arizcorreta A; Díaz F; Roldán R; Martín-Herrera L; Pérez-Guzmán E; Girón-González JA
Clin Infect Dis; 2003 Feb; 36(4):491-8. PubMed ID: 12567308
[TBL] [Abstract][Full Text] [Related]
14. Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.
Phillips E; Gutiérrez S; Jahnke N; Yip B; Lima VD; Hogg RS; Harrigan PR; Montaner JS
AIDS; 2007 Jul; 21(12):1561-8. PubMed ID: 17630551
[TBL] [Abstract][Full Text] [Related]
15. Insulin resistance is not associated with liver fibrosis progression in HIV/hepatitis C virus-coinfected patients.
Merchante N; Macías J; Ramayo E; Vergara S; García-García JA; Mira JA; Corzo JE; Gómez-Mateos JM; Lozano F; Pineda JA
J Viral Hepat; 2006 Jul; 13(7):449-56. PubMed ID: 16792538
[TBL] [Abstract][Full Text] [Related]
16. Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan.
Tseng YT; Yang CJ; Chang SY; Lin SW; Tsai MS; Liu WC; Wu PY; Su YC; Luo YZ; Yang SP; Hung CC; Chang SC
Int J Infect Dis; 2014 Dec; 29():12-7. PubMed ID: 25312984
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection.
Dieterich DT
Am J Med; 1999 Dec; 107(6B):79S-84S. PubMed ID: 10653464
[TBL] [Abstract][Full Text] [Related]
18. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients.
Labarga P; Soriano V; Vispo ME; Pinilla J; Martin-Carbonero L; Castellares C; Casado R; Maida I; Garcia-Gasco P; Barreiro P
J Infect Dis; 2007 Sep; 196(5):670-6. PubMed ID: 17674307
[TBL] [Abstract][Full Text] [Related]
19. Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy.
Fernández-Montero JV; Barreiro P; Vispo E; Labarga P; Sánchez-Parra C; de Mendoza C; Treviño A; Soriano V
Antivir Ther; 2014; 19(3):287-92. PubMed ID: 24192598
[TBL] [Abstract][Full Text] [Related]
20. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients.
Mariné-Barjoan E; Saint-Paul MC; Pradier C; Chaillou S; Anty R; Michiels JF; Sattonnet C; Ouzan D; Dellamonica P; Tran A;
AIDS; 2004 Nov; 18(16):2163-70. PubMed ID: 15577649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
